Stockhammer, Florian

[["dc.bibliographiccitation.firstpage","2093"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","Anticancer Research"],["dc.bibliographiccitation.lastpage","2098"],["dc.bibliographiccitation.volume","33"],["dc.contributor.author","Misch, Martin"],["dc.contributor.author","Czabanka, Marcus"],["dc.contributor.author","Dengler, Julius"],["dc.contributor.author","Stoffels, Mandy"],["dc.contributor.author","Auf, Gregor"],["dc.contributor.author","Vajkoczy, Peter"],["dc.contributor.author","Stockhammer, Florian"],["dc.date.accessioned","2018-11-07T09:25:01Z"],["dc.date.available","2018-11-07T09:25:01Z"],["dc.date.issued","2013"],["dc.description.abstract","Background: The major side-effects of bevacizumab in glioma treatment are venous thromboembolic events (VTE). We retrospectively evaluated factors potentially predictive of thromboembolic events. Patients and Methods: Bevacizumab, alone or in combination with chemotherapy was used as salvage therapy for recurrence in malignant glioma every two weeks. None but one patient received anticoagulants. Before each bevacizumab cycle differential blood cell count, kidney and liver parameters, D-dimers, neurological status, body-mass index, vital signs and signs of venous thrombosis were assessed. Results: Thirty-eight patients received 428 cycles of bevacizumab. In five patients (13%), six VTE were observed. These complications were preceded four weeks before the onset of symptoms by D-dimer elevation above 0.865 mg/l [p<0.0001; sensitivity=89% (95% confidence interval=83-93%); specificity=89% (95% CI=52-100%)]. An existing hemiparesis constituted a 27-fold risk elevation for thrombotic complication (p<0.0001, chi(2)-test). Conclusion: D-Dimer elevation or hemiparesis predict VTE under bevacizumab and chemotherapy, four weeks before the event becomes clinically apparent. Future investigations should determine if prophylactic anti-coagulants for patients at risk may reduce the risk of VTE."],["dc.identifier.isi","000319233100039"],["dc.identifier.pmid","23645760"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/29972"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Int Inst Anticancer Research"],["dc.relation.issn","0250-7005"],["dc.title","D-Dimer Elevation and Paresis Predict Thromboembolic Events During Bevacizumab Therapy for Recurrent Malignant Glioma"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","252"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","Neurosurgery"],["dc.bibliographiccitation.lastpage","262"],["dc.bibliographiccitation.volume","83"],["dc.contributor.author","Thomale, Ulrich-Wilhelm"],["dc.contributor.author","Schaumann, Andreas"],["dc.contributor.author","Stockhammer, Florian"],["dc.contributor.author","Giese, Henrik"],["dc.contributor.author","Schuster, Dhani"],["dc.contributor.author","Kästner, Stefanie"],["dc.contributor.author","Ahmadi, Sebastian A."],["dc.contributor.author","Polemikos, Manolis"],["dc.contributor.author","Bock, Hans-Christoph"],["dc.contributor.author","Gölz, Leonie"],["dc.contributor.author","Lemcke, Johannes"],["dc.contributor.author","Hermann, Elvis"],["dc.contributor.author","Schuhmann, Martin"],["dc.contributor.author","Beez, Thomas"],["dc.contributor.author","Fritsch, Michael"],["dc.contributor.author","Orakcioglu, Berk"],["dc.contributor.author","Vajkoczy, Peter"],["dc.contributor.author","Rohde, Veit"],["dc.contributor.author","Bohner, Georg"],["dc.date.accessioned","2018-10-10T07:14:06Z"],["dc.date.available","2018-10-10T07:14:06Z"],["dc.date.issued","2018-08-01"],["dc.description.abstract","Freehand ventricular catheter placement may represent limited accuracy for the surgeon's intent to achieve primary optimal catheter position.To investigate the accuracy of a ventricular catheter guide assisted by a simple mobile health application (mhealth app) in a multicenter, randomized, controlled, simple blinded study (GAVCA study). In total, 139 eligible patients were enrolled in 9 centers. Catheter placement was evaluated by 3 different components: number of ventricular cannulation attempts, a grading scale, and the anatomical position of the catheter tip. The primary endpoint was the rate of primary cannulation of grade I catheter position in the ipsilateral ventricle. The secondary endpoints were rate of intraventricular position of the catheter's perforations, early ventricular catheter failure, and complications. The primary endpoint was reached in 70% of the guided group vs 56.5% (freehand group; odds ratio 1.79, 95% confidence interval 0.89-3.61). The primary successful puncture rate was 100% vs 91.3% (P = .012). Catheter perforations were located completely inside the ventricle in 81.4% (guided group) and 65.2% (freehand group; odds ratio 2.34, 95% confidence interval 1.07-5.1). No differences occurred in early ventricular catheter failure, complication rate, duration of surgery, or hospital stay. The guided ventricular catheter application proved to be a safe and simple method. The primary endpoint revealed a nonsignificant improvement of optimal catheter placement among the groups. Long-term follow-up is necessary in order to evaluate differences in catheter survival among shunted patients."],["dc.fs.pkfprnr","44523"],["dc.identifier.doi","10.1093/neuros/nyx420"],["dc.identifier.fs","633504"],["dc.identifier.pmid","28973670"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/15918"],["dc.language.iso","en"],["dc.notes.status","final"],["dc.relation.eissn","1524-4040"],["dc.title","GAVCA Study: Randomized, Multicenter Trial to Evaluate the Quality of Ventricular Catheter Placement with a Mobile Health Assisted Guidance Technique"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","92"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Neuro-Oncology"],["dc.bibliographiccitation.lastpage","102"],["dc.bibliographiccitation.volume","16"],["dc.contributor.author","Hutterer, Markus"],["dc.contributor.author","Nowosielski, Martha"],["dc.contributor.author","Haybaeck, Johannes"],["dc.contributor.author","Embacher, Sabine"],["dc.contributor.author","Stockhammer, Florian"],["dc.contributor.author","Gotwald, Thaddaeus"],["dc.contributor.author","Holzner, Bernhard"],["dc.contributor.author","Capper, David"],["dc.contributor.author","Preusser, Matthias"],["dc.contributor.author","Marosi, Christine"],["dc.contributor.author","Oberndorfer, Stefan"],["dc.contributor.author","Moik, Martin"],["dc.contributor.author","Buchroithner, Johanna"],["dc.contributor.author","Seiz, Marcel"],["dc.contributor.author","Tuettenberg, Jochen"],["dc.contributor.author","Herrlinger, Ulrich"],["dc.contributor.author","Wick, Antje"],["dc.contributor.author","Vajkoczy, Peter"],["dc.contributor.author","Stockhammer, Guenther"],["dc.date.accessioned","2018-11-07T09:46:59Z"],["dc.date.available","2018-11-07T09:46:59Z"],["dc.date.issued","2014"],["dc.description.abstract","Background. Due to the redundancy of molecular pathways simultaneously involved in glioblastoma growth and angiogenesis, therapeutic approaches intervening at multiple levels seem particularly appealing. This prospective, multicenter, single-arm phase II trial was designed to evaluate the antitumor activity of sunitinib, an oral small-molecule inhibitor of several receptor tyrosine kinases, in patients with first recurrence of primary glioblastoma using a continuous once-daily dosing regimen. Patients received a starting dose of sunitinib 37.5 mg, followed by a maintenance dose between 12.5 mg and 50 mg depending on drug tolerability. The primary endpoint was a 6-month progression-free survival (PFS) rate. Secondary endpoints included median PFS, overall survival (OS), safety/toxicity, quality of life, and translational studies on the expression of sunitinib target molecules. Forty participants were included in this study, and no objective responses were detected. PFS6 was 12.5, median PFS 2.2 months, and median OS 9.2 months. Five participants (12.5) showed prolonged stable disease 6 months with a median PFS of 16.0 months (range, 6.441.4 mo) and a median OS of 46.9 months (range, 21.249.2 mo) for this subgroup. c-KIT expression in vascular endothelial cells (n 14 participants) was associated with improved PFS. The most common toxicities were fatigue/asthenia, mucositis/dermatitis, dysesthesias, gastrointestinal symptoms, cognitive impairment, leukoctopenia, and thrombocytopenia. Two participants (5) terminated treatment due to toxicity. Continuous daily sunitinib showed minimal antiglioblastoma activity and substantial toxicity when given at higher doses. High endothelial c-KIT expression may define a subgroup of patients who will benefit from sunitinib treatment by achieving prolonged PFS."],["dc.identifier.doi","10.1093/neuonc/not161"],["dc.identifier.isi","000329135900012"],["dc.identifier.pmid","24311637"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/35009"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Oxford Univ Press Inc"],["dc.relation.issn","1523-5866"],["dc.relation.issn","1522-8517"],["dc.title","A single-arm phase II Austrian/German multicenter trial on continuous daily sunitinib in primary glioblastoma at first recurrence (SURGE 01-07)"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","15"],["dc.bibliographiccitation.journal","Journal of Clinical Oncology"],["dc.bibliographiccitation.volume","33"],["dc.contributor.author","Wick, Wolfgang"],["dc.contributor.author","Roth, Patrick"],["dc.contributor.author","Wiestler, Benedikt"],["dc.contributor.author","Hartmann, Christian"],["dc.contributor.author","Hau, Peter"],["dc.contributor.author","Nakamura, Makoto"],["dc.contributor.author","Stockhammer, Florian"],["dc.contributor.author","Sabel, Michael"],["dc.contributor.author","Koeppen, Susanne"],["dc.contributor.author","Ketter, Ralf"],["dc.contributor.author","Vajkoczy, Peter"],["dc.contributor.author","Eyupoglus, Ilker"],["dc.contributor.author","Kaendler, Stephen"],["dc.contributor.author","Kalff, Rolf"],["dc.contributor.author","Galldiks, Norbert"],["dc.contributor.author","Schmidt-Graf, Friederike"],["dc.contributor.author","von Deimling, Andreas"],["dc.contributor.author","Platten, Michael"],["dc.contributor.author","Reifenberger, Guido"],["dc.contributor.author","Weller, Michael"],["dc.date.accessioned","2018-11-07T09:57:08Z"],["dc.date.available","2018-11-07T09:57:08Z"],["dc.date.issued","2015"],["dc.identifier.isi","000358036900460"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/37097"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Amer Soc Clinical Oncology"],["dc.publisher.place","Alexandria"],["dc.relation.conference","Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)"],["dc.relation.eventlocation","Chicago, IL"],["dc.relation.issn","1527-7755"],["dc.relation.issn","0732-183X"],["dc.title","Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1529"],["dc.bibliographiccitation.issue","11"],["dc.bibliographiccitation.journal","Neuro-Oncology"],["dc.bibliographiccitation.lastpage","1537"],["dc.bibliographiccitation.volume","18"],["dc.contributor.author","Wick, Wolfgang"],["dc.contributor.author","Roth, Patrick"],["dc.contributor.author","Hartmann, Christian"],["dc.contributor.author","Hau, Peter"],["dc.contributor.author","Nakamura, Makoto"],["dc.contributor.author","Stockhammer, Florian"],["dc.contributor.author","Sabel, Michael C."],["dc.contributor.author","Wick, Antje"],["dc.contributor.author","Koeppen, Susanne"],["dc.contributor.author","Ketter, Ralf"],["dc.contributor.author","Vajkoczy, Peter"],["dc.contributor.author","Eyupoglu, Ilker"],["dc.contributor.author","Kalff, Rolf"],["dc.contributor.author","Pietsch, Torsten"],["dc.contributor.author","Happold, Caroline"],["dc.contributor.author","Galldiks, Norbert"],["dc.contributor.author","Schmidt-Graf, Friederike"],["dc.contributor.author","Bamberg, Michael"],["dc.contributor.author","Reifenberger, Guido"],["dc.contributor.author","Platten, Michael"],["dc.contributor.author","von Deimling, Andreas"],["dc.contributor.author","Meisner, Christoph"],["dc.contributor.author","Wiestler, Benedikt"],["dc.contributor.author","Weller, Michael"],["dc.date.accessioned","2018-11-07T10:06:29Z"],["dc.date.available","2018-11-07T10:06:29Z"],["dc.date.issued","2016"],["dc.description.abstract","Background. Optimal treatment and precise classification for anaplastic glioma are needed. Methods. The objective for long-term follow-up of NOA-04 is to optimize the treatment sequence for patients with anaplastic gliomas. Patients were randomized 2: 1: 1 to receive the standard radiotherapy (RT) (arm A), procarbazine, lomustine and vincristine (PCV) (arm B1), or temozolomide (TMZ) (arm B2). Results. Primary endpoint was time-to-treatment-failure (TTF), defined as progression after 2 lines of therapy or any time before if no further therapy was administered. Exploratory analyses examined associations of molecular marker status with TTF, progression-free survival (PFS), and overall survival (OS). At 9.5 (95% CI: 8.6-10.2) years, no difference between arms (A vs B1/B2) was observed: median TTF (4.6 [3.4-5.1] y vs 4.4 [3.3-5.3) y), PFS (2.5 [1.3-3.5] y vs 2.7 [1.9-3.2] y), and OS (8 [5.5-10.3] y vs 6.5 [5.4-8.3] y). Oligodendroglial versus astrocytic histology-but more so the subgroups according to CpG island methylator phenotype (CIMP) and 1p/19q co-deletion status-revealed a strong prognostic value of CIMPpos with (CIMPcodel) versus without 1p/19 co-deletion (CIMPnon-codel) versus CIMPneg. but no differential efficacy of RT versus chemotherapy for any of the endpoints. PFS was better for PCV-than for TMZ-treated patients with CIMPcodel tumors (HR B1 vs B2 0.39 [0.17-0.92], P = .31). In CIMPneg. tumors, hypermethylation of the O6-methyl-guanyl-DNA methyltransferase promoter (MGMT) provided a risk reduction for PFS with chemotherapy. Conclusions. There is no differential activity of primary chemotherapy versus RT in any subgroup of anaplastic glioma. Molecular diagnosis is superior to histology. Trial Registration: clinicaltrials.gov Identifier: NCT00717210."],["dc.identifier.doi","10.1093/neuonc/now133"],["dc.identifier.isi","000387330300009"],["dc.identifier.pmid","27370396"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/39103"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.relation.issn","1523-5866"],["dc.relation.issn","1522-8517"],["dc.title","Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dspace.entity.type","Publication"]]